Zydus Lifesciences gains on getting USFDA`s final nod for Diclofenac Sodium and Misoprostol Delayed Release tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 520.35, up by 2.65 points or 0.51% from its previous closing of Rs. 517.70 on the BSE.
The scrip opened at Rs. 522.60 and has touched a high and low of Rs. 523.15 and Rs. 515.85 respectively. So far 29575 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 530.70 on 09-May-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 523.15 and Rs. 504.15 respectively. The current market cap of the company is Rs. 52346.14 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg (USRLD: Arthrotec Delayed-Release Tablets).
Diclofenac belongs to nonsteroidal anti-inflammatory drug (NSAID) group of medicines. It works by reducing substances in the body that cause pain and inflammation. Misoprostol reduces stomach acid and replaces protective substances in the stomach that are reduced by NSAIDs. Misoprostol protects the lining of the esophagus, stomach and intestines while taking diclofenac. Diclofenac Sodium and Misoprostol Delayed Release Tablets are used to treat osteoarthritis and rheumatoid arthritis in people at high risk for developing stomach or intestinal ulcers. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of $13 million in the United States (IQVIA MAT March 2023). The group now has 373 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
